TLPH
Talphera, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$1.20
+0.00%Year over year
Reported trailing growth
- Revenue
- -96.3%
- EBITDA
- -42.2%
- EBIT
- -10.4%
- EPS
- +20.5%
- Free cash flow
- -5.7%
- Operating cash flow
- -5.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +82.9%
- EPS
- +38.1%
Three-year CAGR
- Revenue
- -79.3%
- EBITDA
- -14.8%
- EBIT
- +11.6%
- Net income
- -9.9%
- EPS
- +32.0%
- Free cash flow
- +10.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026